Basilea awarded additional CARB-X funding of USD6million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study…
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08,…
